- Home
- NTRP vs NERV Comparison
NTRP vs NERV Comparison
Compare NTRP & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTRP
- NERV
- Stock Information
- Founded
- NTRP 1985
- NERV 2007
- Country
- NTRP United States
- NERV United States
- Employees
- NTRP N/A
- NERV N/A
- Industry
- NTRP
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- NTRP
- NERV Health Care
- Exchange
- NTRP NYSE
- NERV Nasdaq
- Market Cap
- NTRP 12.7M
- NERV 12.4M
- IPO Year
- NTRP N/A
- NERV 2014
- Fundamental
- Price
- NTRP $2.05
- NERV $1.54
- Analyst Decision
- NTRP Hold
- NERV Hold
- Analyst Count
- NTRP 1
- NERV 1
- Target Price
- NTRP $5.00
- NERV $5.00
- AVG Volume (30 Days)
- NTRP 295.1K
- NERV 7.8K
- Earning Date
- NTRP 06-10-2025
- NERV 05-13-2025
- Dividend Yield
- NTRP N/A
- NERV N/A
- EPS Growth
- NTRP N/A
- NERV N/A
- EPS
- NTRP N/A
- NERV 0.83
- Revenue
- NTRP $501,422.00
- NERV N/A
- Revenue This Year
- NTRP $354.28
- NERV N/A
- Revenue Next Year
- NTRP $536.37
- NERV N/A
- P/E Ratio
- NTRP N/A
- NERV $1.86
- Revenue Growth
- NTRP 186.93
- NERV N/A
- 52 Week Low
- NTRP $1.39
- NERV $1.15
- 52 Week High
- NTRP $8.50
- NERV $3.69
- Technical
- Relative Strength Index (RSI)
- NTRP 40.18
- NERV 48.69
- Support Level
- NTRP $1.72
- NERV $1.48
- Resistance Level
- NTRP $2.21
- NERV $1.55
- Average True Range (ATR)
- NTRP 0.23
- NERV 0.12
- MACD
- NTRP 0.06
- NERV 0.00
- Stochastic Oscillator
- NTRP 42.86
- NERV 54.55
About NTRP NEXTTRIP INC
NextTrip Inc is a technology-driven platform delivering travel booking and travel media solutions. It provides individual and group travelers with vacations to popular and sought-after destinations in Mexico, the Caribbean, and across the world. NextTrip Media platform - Travel Magazine offers a social media platform for viewers to explore, educate, and share with friends their bucket list travel. The company is also launching an end-to-end content ecosystem that uses AI-assisted travel planning capturing advertising, building brand awareness, rewarding loyalty, and driving bookings.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.